Ex-Puma ex­ec sen­tenced to prison stretch on in­sid­er-trad­ing con­vic­tion — 'greed' made me do it

Puma Biotech­nol­o­gy’s $PBYI for­mer head of reg­u­la­to­ry af­fairs will be spend­ing the next cou­ple of years in prison, serv­ing a sen­tence for in­sid­er trad­ing af­ter tak­ing a guilty plea last fall.

The lat­est in a long string of in­sid­er trad­ing cas­es in biotech fea­tures Robert Gadimi­an, who had to pay up af­ter the SEC ac­cused him of pock­et­ing more than $1 mil­lion in il­lic­it stock gains. Gadimi­an used his in­sid­er knowl­edge at Puma to get the scoop on ner­a­tinib, buy­ing shares just ahead of tri­al re­sults in 2013 and 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER